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The Stevens–Johnson syndrome (SJS) is a life-threatening skin
condition caused by a hypersensitivity complex, which affects the
skin and the mucous membranes. This syndrome is closely related
to the application of antiepileptic drugs (AEDs).1 Most cases are
caused by aromatic AEDs, such as phenytoin, carbamazepine,
oxcarbazepine, phenobarbital, lamotrigine, and other aromatic
drugs.2 Levetiracetam (LEV), the S-enantiomer ofa-ethyl-2-oxo-1-
pyrrolidine acetamide, is an AED with a novel mechanism of
action.3 Arif et al. reviewed 1890 cases and determined the
predictors and relative incidences of AED-related rash in patients
who take 15 different AEDs. In that study, 0.6% of the patients who
started LEV treatment developed rashes.4 To the best of our
knowledge, the current paper presents the ﬁrst case report on LEV
therapy-induced SJS in a child. LEV-induced cutaneous drug
eruptions are rare. However, the case discussed in this work may
be useful for AED selection and counseling of individual patients.
2. Case
A female patient, 2.25 years old, underwent hypothermic open
heart surgery for congenital heart disease with a pulmonary artery
sling, ventricular septal defect, patent ductus arteriosus, and cleft
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temperature was normal. Cardiorespiratory arrest occurred on
the seventh day after her operation. She was treated with tracheal
cannulation and ventilator-assisted respiration. Seizures occurred
on the eighth day after her operation so she was given
phenobarbital at 5 mg/kg/day. Considering her declining status
and poorly controlled seizures, 10 mg/kg/day oxcarbazepine (OXC)
was added on the 32nd day post-operation. Rashes began to appear
on her torso, and her body temperature reached 37(8 8C on the
34th day (i.e., two days after OXC was administered). On the 35th
day, she developed on her torso an erythematous maculopapular
rash without exudates, which grew pale upon pressure. Consider-
ing OXC allergy, the drug was changed to LEV (20 mg/kg/day).
Upon subsequent observation, rashes no longer developed, and the
primary rash began to disappear. The ventilator was no longer
required on the 39th day after operation. However, LEV dosagewas
increased to 30 mg/kg/day on the 41st day, because the seizures
began to recur frequently. Once again, her body temperature
increased, reaching up to 38.8 8C. Moreover, the rashes developed
again on the ninth day after LEVwas administered. On the 50th day
post-operation, her body temperature reached 40 8C. The feverwas
persistent, and more rashes appeared on her face and torso, which
spread to all four limbs. The rashes on her facewere conﬂuent with
patchy congested areas; these rashes were similar to herpes
erosions. Exudation occurred on her mouth and lips. As her illness
progressed, the erosions and exudation appeared on the mucous
membranes of her vulva and anus (Fig. 1). She was then diagnosed
with SJS, which may have been caused by LEV. LEV was stopped
immediately, and methylprednisolone (20 mg/kg/day) was added
to her drug regimen. In addition, skin and membrane care was
enhanced to avoid secondary infections and maintain the function
of the internal organs without contacting other allergens. Her ﬂuid
and caloric intake was carefully controlled. Topiramate was used
as the primary AED. Her body temperature returned to normal two
days after LEV was withdrawn (on the 52nd day post-operation).
No new rashes appeared on the 58th day. The rest of her stay
became normal. She continued to take phenobarbital and
topiramate and was discharged from the hospital on the 88th
day after her operation (Fig. 2).
3. Discussion
Antiepileptic drug hypersensitivity syndrome (AHS) is a
relatively rare side effect of Antiepileptic drugs (AEDs), and rangesvier Ltd. All rights reserved.
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Fig. 1. Rashes appeared on her face and torso that spread to all four limbs. The rashes on her face were conﬂuent with patchy congested areas and were similar to herpes
erosions and exudation occurred on her mouth and lips on the nine days after increasing the Levetiracetam dosage (30/kg/day).
[(Fig._2)TD$FIG]
Fig. 2. Abscissa (x-axis): Days after surgery. Ordinate (y-axis): Antiepileptic drug use of time, the time the rash appears and the body temperature seen.
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drome or toxic epidermal necrolysis.2 AHS is closely related to the
application of AEDs, and most of them are caused by the aromatic
AEDs, such as phenytoin, carbamazepine, and other aromatic
drugs. It can also be caused by drugs such as dapsone. The
syndrome is deﬁned by the triad of fever, skin rash, and internal
organ involvement. The incidence occurs in approximately 1 in
3,000 exposures.2 Hypersensitivity syndrome reactions to AEDs
are associated with severe clinical cutaneous adverse reactions
(SCAR).5 SCAR to drugs include acute generalized exanthematous
pustulosis, drug reaction with eosinophilia and systemic symp-
toms (DRESS syndrome or also called drug-induced hypersensi-
tivity syndrome), SJS, and toxic epidermal necrolysis.6
SJS is an uncommon but potentially life-threatening idiosyn-
cratic drug reaction usually caused by aromatic anticonvulsants.
The importance of early diagnosis and ability to distinguish SJS
from other diseases cannot be overemphasized, because the risk is
largely conﬁned to the ﬁrst two months of treatment.1 Patients
who receive LEV treatment rarely develop rashes.2 In cases of AED
allergy, doctors choose LEV as an alternative drug. SJS is not a
reported side effect of LEV. Alkhotani7 reported a case of LEV-
induced angioedema in a patient with a previous anticonvulsant
hypersensitivity reaction to phenytoin and lamotrigine. The
reported case is very similar to the case presented in the current
paper.7 Thus, a question arises: can a patient with a known sulfa
allergy receive LEV treatment? The previous case7 and the case we
present in this paper reveal that LEV allergy occurs in patients with
previous anticonvulsant hypersensitivity reactions. However,
attention should also be given to the cross-reactivity betweendrugs. The cross-reactivity between phenytoin, carbamazepine,
and phenobarbital is as high as 70.40%.8 The most common cases
involve aromatic drugs that exhibit signiﬁcant cross-reactivity due
to large differences among their chemical structures.9 By contrast,
other AEDs such as LEV, topiramate, gabapentin, and tiagabine are
rarely associated with rashes. Wang et al.10 reviewed the medical
records of all AED treatments in 3,793 consecutive Chinese
patients with epilepsy in our hospital. Hirsch et al.11 reviewed
the incidence of AED-related rash in 1,875 outpatients. However,
some studies have reported cases of dose-related LEV-induced
reticulated drug eruption,12 LEV-induced drug reaction with
eosinophilia and systemic symptom syndrome,13 and severe acute
hepatitis in DRESS syndrome.14 Although LEV is rarely associated
with cutaneous adverse reactions, clinicians should be aware of its
potential to cause hypersensitivity syndrome reactions.
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